ICML 2023 | Tafasitamab at the blood-brain barrier: exploring this agent for the treatment of CNS lymphoma
James Rubenstein, MD, PhD, University of California San Francisco, San Francisco, CA, shares some insights into the safety and efficacy of tafasitamab for the treatment of CNS lymphoma. Dr Rubenstein discusses the rationale behind exploring this agent and further comments on how tafasitamab may impact the blood-brain barrier. Following this, Dr Rubenstein discusses a case study of a patient with relapsed/refractory (R/R) CNS lymphoma who responded to the combination of tafasitamab and lenalidomide (tafa-len), which is now being evaluated in a Phase I/II trial. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
